Basal non-cholesterol sterols reveal a subgroup of 4S not benefitted by simvastatin-induced decrease of recurrent coronary events  by Miettinen, T.A. & Gylling, H.
JACC Fcbrua~ I~ AB~'IRACT$ - P.,,zer -~eIA 
vs 701, IP =, 0.02), systolic hyperten=ion (53% vs 42~, p = 003), dmbetes 
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C,E. I~t~Os. J,D. ~ ,  JN. Skoumas, CI. A~i ,  S,G, I~lrnbrou, 
A.A, F ~ ,  C!, S te~,  PK Toutouzas L ~  at Ca~/~,  
~zrzlt~z~ut~ ~ ~ hyp~retemla  (hFH) Is assocq- 
ated wire an ~ risk of ~ .  The aim of mm sludy was Io 
datem'dne me evofulmn el daseendl~g thorac¢ aomz alhemmatous dmease 
(TAA) by ~ erhoca~gfa l~ (lqEE) m hFl-I patients after 
Io~-tem~ ~ mera~t ~ d~ and stam~r,. Sixteen patrols (7 
maim and 9 ~male~ mean age 47 ~ 12 yrs) wilh f~y  diagnoe, d hFH 
o:~mpased the study populatk0~t. An p~beofs unOefwerff a baseline TEE ex- 
aalatat~ ~r  wl~dl ~ ¢'t~[31 (:rz~1 alibi p r ' ~  (L~[)-40 n~ o.d) were 
initiated. ~ t  TEE was ped~m~ed after 2 y,zs of therapy. TAA was graded 
as follows: grede 0: no,real i r~a;  g~de |: inoreased intimal ecbede~s~ 
lh~ck~H~l o r lunlen t~j.d~t~; ~cld~. It: ~ illt~mal 
s~ w~h sm~ ~dl-defmed ameromatous i~que proWudmg .:3 mm intothe 
lun, m~ grade IlL ~ allleremas I~01n~ng <3 ram; grade IV: atheremas 
protmdm0 >3 n~ glade V: protmdm9 mollie of pedunculated ptaquas. 
~ :  As a result o~ treofment, LDL decreasea frem 294 _+ 56 n~O/dl to 
193 ~ 56 n~'dl (p < 0.025). Accoofin9 te beselme TEE, I pt was grada 0, 4 
pts were grade I, 6 pts were grade II, 3 pts were grade III and 2 were grade 
IV. Two years lat~ 7 pts did not change c~tegory, 3 pts showed prograsS~on 
of TAA (1 pt flora, gr-~de II to grade Ill and 2 pts from grade III to grade IV), 
v~le 6 pts showed re~-esston ot TAA (3 pts from made t to grade. 0 I~  
tram ~ It to grade o. 1 pt from It to ! and 1 pt from IV to III). Paben~ 
who improved We~B younger (39 ± 14 vs 52 ± 6 yrs, p < 0.025) rind less 
severe pretreatment TAA and had a greater LDL decrease (138 ± 56 vs 72.5 
54.5 mg,k;g, p < 0.025), compared with patients who remained stable or 
deteriorated. 
In ~on.  ior~ten'~ hypot@Ktemic d~et and treatment v~th pravestatm 
is ettectwe in produ~m~j TAA regressmn in young hFH pts with moderate 
atheromatesis. TEE is a v'alual~e method for the evaluation of these changes. 
' -~  Pravastatin Reduces Total in Patients With Mortel~y 
Coronary Heart Disease and A~,rage Cholesterol 
Levels: Relationship of Baseline Cholesterol and 
Treatment Effects in the LIPID 11rlal 
R.J. Simes. J. Baker. S. MacMahon. W. Hague. D. Colquhoun. M. West. 
M. Arulchelvam, J. Shaw. A. Tonkin. On behaff of the LIPID stu~ group: 
University of Syclrmy: National Hear Foundation. Australia 
Despite benefits of cholesterol owering treatment seen in eadier tnats, treat- 
ment effect on mortality in patients ,~th relat~ety hernial cholesterol levels 
has remained uncertain. The LIPID trial assessed long term effects of pravas- 
latin versus p~acebo ~n 9,104 patients with baseline total choleste rot of 4.0.-7.0 
mmol/L (155-271 m~cli) and a history of acute myocardial infarction (5,754; 
64%) or hospitalisation for unstable angina (3,260; 361). Major treatment 
outcomes included coronary mortality, total mortality, myocardial infarction, 
and stroke. The study was also designed to assess treatment effects by 
baseline lipids and changes in lipids on subsequent outcomes. The study 
included large numbers with relatively tow initia| cholesterol evels: 3,793 
(42%) with total cholasterol <5.5 mmoPL (213 mg]dl) and 2,678 (,30°/,4 v~th 
LDL cholesterol <3.5 mmol,l_ (136 mg/dl). 
Interim analysis has shown clear evidence of a reduction in total mortality 
with pravastatin (p < 0.003) and so the LIPID trial is clesing early with final 
analysis to be undertaken after patient visits are completed by September 30, 
1997. The relationship between baseline lipid levels and relative reductions 
in coronary events will be examined as well as the effect of lipid changes on 
subsequent coronary risk. Th=s large scale trial should enable the relationship 
of treatment effects with pravastatin and lipids to be estimated much more 
reliably. 
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¢~t~In ,  s Novel HMG.CoA lqeducte~ Inhlbltor 
E. Stein ~ , J. lsaac~o~n ~ , R Stollz~. A Mazzu ~, IV.,C Li~, C, l.~me ~, 
A,H, Helk~P, 'Me~ and/ At't'teft~¢~rot,~ F ,~ch Cw~', Cmcmn, M~, 
OH, USA; ~ GFI I ~ ~ ~ , I ~ 4 ~  L~vatl~ ,  IN, ~;  ,~  
C~at~,  P~atm~em~ Ptvm~ vV~t ~1.  CT, USA 
C~f~v~n (CER) m a~ novel HMG.COA n~:luc~ mt~ltef I~  reduel~ 
chek~-leml level= ~t ~r~tow 00~es. Pmv~ ~tu~e~ up Io 0.¢ ~} pmdu¢~ 
a Io9 I~r  ¢lo~mspomm cu~ wflh LOL-¢bOk~t~ol (LDL.C) ~ of 
36%. 
~ -  To c~m,m~_ em ~ e~l ufmy at rERm 0,O m0~y 
~ -  In th~ 2B day mndomt~t~ doub~-bl~, pla¢~o (PLA),o~.. 
troUe¢l ~ II If~, 41 pltl~l~ ~ ~ ~ , , a  m 
t~ll~lL,~ on an AHA Ste~ I diet foe 4 'MN~J l~f  t~ ~ tO CER 
0.8 mO (n = 281 or PL~ (n = 13), ¢l~ly tn Ihe evef~l, LOL¢, t0tal rhOle~4m:d 
(1oral.C), HOL.C, ~ (TRIG) lind Lp(a) wefli~  m ~-...~,~ 
i ~ ,  All adv~me veofs were ~ .  
F~U/IS.' Chan~ =n I~  par~ (% from harm at each post,treat. 
ment vmtl) were as ~low~: 
Day a Day 1,5 Day 22 Day 29 
Parameter PLA CER PLA CER PLA CER Pl~ CER 
LDL-C F.0 -325 41 -37,?. 31 -434 1 2 -440 
To~aI.C 1 7 239 2.4 ~2e3 3.7 -301 ~ -30e 
HOL-C 20 20 - t2 1.0 31 2e -12 32 
TRIG -43 -14.5 t02 -18.9 96 -B7 159 -112 
CER s~gmficamty reduced tetal-C, LDL-C and l~ty~ftde ~ compare0 
m PLA Reduction~ m IoW-C and LDL-C were appmem after a days, and 
mammal by Day 22. All !paints completed the 2&-day treatment course. 
Ot~e patient, m the Iou~t~ week of treatme~ wilh CER, day.aped peh~c 
i n ~  disease. No patient e~l~ited ALT or AST elevatJ~ greater 
man2 ,, ULN. One patent, t~ l~ l  w~h CER a~e¢ l  an a~,pton-.a~ 
inc~rease in CK (8 ~ ULN) oft gle last day of Irealm~t. This value relumed 
to near nownel mx days la~. 
~ :  CER 0.8 mg produced an LDL-C raduction of 441 eon=s~mt 
with a continued tog linear dose ~ of 6% adl~nal LDL-C reduction 
for every CtDu~ng el dose. This rs~tt.¢tton m¢ompara~a with the t~he~ 
doses of the most effective stat~rts cu~ marketed 
[ -~- -~ Sitostanol ~ Added to Long-tern1 Shnvamatln 
Treatment of Coronary Patients With Low and High 
Basal Cholesterol Absorpt ion 
H. Gylling, T.A. Mietllnen. Oepar/ment o: Medcm~ Unme~rty of" t-telslnkl. 
Fin/and 
Ba~grounu. A simvastatm-treated subgroup, not reduong recurrence oi ma. 
lor coronary e~s ,  was ,~Bparaled horn 45 by high ba~d seru~ cholestanol 
and plant sterol and low precursor sterol ratios suggesting that they had 
hfgh absotpl~m and low synff~emis of cholesterol. We assumed tt~t the 
non-respon~rs might be more ~ to ~ostand est~ mmgmme 
(SEM)-induced c~asterel ma~L-~on.  
Method: From a coronary group treated over a year with stmvastatm, 
higllest (H;n = 15) and lowest (L'n = 15) absorbers were s~Heofed by glair 
basal chofestano~cholesterel ratio and treated for 3 monff~ with SEM. 
Resu/ts.- Basal total and LDL choleslerel values and 1heir simvaMalkl-ln- 
duced redudions were similar in H and L while the re~:,~h/e cholestrnol 
and plant sterol ratios were 1.6-1,9 times higher in H than L Addition of SEM 
further decreased total (-7.6 ± 2~/=) and LDL (-11.7 + 3.51) cholesterol 
in H (P < 0.01). while in L the reductions were nonsignificant. Reductions 
of cholestanol and plant sterol ratios and the increases of precursor sterol 
ratios were similar in the two groups. 
Conclusion: Coronary patients on simvastattn with high baseline rhotas- 
tarot absorption are benefitled tram sttostanol-induced cholesterol malab- 
sorption as compared to those w~th.low absorption and high synthesis. Non- 
responsiveness to stalin may contribute to lacking recurrence of coronary 
events. 
~ Basal Non-cholesterol Sterol$ Reveal a Subgroup 
of 4S Not Benefitted by Slmvesttltin-lnduced 
Decrease of Recurrent Coronary Events 
T.A. Miettinen, H, Gylling. Department of Medicine, University of He/sinki, 
Finland 
Ba,.,~ground: InScandinavian Sir'm, astatin Survival Study (4S) stmvestatin-in- 
duced ,eduction of coronary events (CE) was not predicted by baseline Iipids. 
The increasing quartiles at the t~as~l cholesterol (C) precursor steml (IS)/C 
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rntlt ~, the cholestanol (Oh) and plant storol (PS)/C ratios, two sterol groups 
rofle,:tlng synthesis and absorption of C, respectively, and felting blood 
glucose wore related to CE In Finnish slmvostatin (n = 435) and placebo (n 
,-= 432) subgroups of 4S. 
Roslllt~: The relative ri~k of CE was ~tgntficantly reduced by slmvastntin 
in the lowest (risk ratio lot Ch 0,623;95% CI 0,395-0,982) but not in the 
highest quartile (risk ratio t,166;95% CI 0,791-1,72), The relative dsk was 
2,2 times higher (P < 0,0t) In tile lowest thnn the highest quartile, PS npd 
e~poclnlly IS wore leas consistent predl¢tom, Increasing basal Ch end PS 
qusrtlles were associated wtth do(xenslng IS, triglycertdo, BMI and blood 
glucose (without or with dlsbote~), and Increasing HDL r, hole~terol qundiles, 
81mvas~,dln.troatod subjn(~t~ wllh recurrent CE was Iho only subgroup not 
rodtlclng blood gtusoso with Ingressing Ch qtlarttle, 
Con~/o~on: Coronas/subje(~ts with high basal absorption nnd low syn- 
thesis of ¢holosferel are not benelittod by reduced recurrence el eoronnw 
events during simvastatin trnatmnm, 
~ ' ~  Lesion Progression, Regression, and Stability With 
Fluvaatatln/n the Llpoproteln and Coronary 
Atheroaelaroals Study 
C,M Ballantyne, J,A, Herd, JK, Dnnn, L,L Fndic, A,M eerie, Jr. L)avlor 
Cotl~g~ et ^ .f~c~l~in~, Hal~fon, IX, (l~A 
Plsqus rapture in thought to be the clltiottl event lending to unstable angina 
and MI, bet most plaque ruptures are asymptomalic nnd lead to lesion 
progression (proS), Angiograph~c trials wiIh staflns have shown clinical event 
reductions granter tl~nn Ihe, modest avorag~ A nllnimum lumen diameter 
tAMLD), e l  1215 lesions in 3,10 pts, only 18P~ (15%) le~tens had prod as 
tlefined by MLD docma~e ~()4 ram, and only 63 (5%) had regression (reSt) 
as defined by MLD Incrosse , 0,4 ram, the remaining t~g%, were stable. Fewer 
tluv~staltn (FL) pin categorized by maximal AMLD as dehnod above had prng 
(54 pts with 73 le,~lons wlll~ proS) thnn plneobo (13 pts wilh 111 lesions with 
ProW, and FL significantly improved the distribution el pts among catogones 
(p ~= 0.04) aa ,~hown below, with ~mnll dltforonces in moan \MLD within each 
category. 
Ping ,ql~I',lo Re~Ii 
n av9 .\MLD n avg .\MLD _~ . . . .  2tv~j~MLD 
FL 54 02B q2 ~O 02 25 ,n 26 
Ping 73 029 ~2 9 0t 14 ,o 23 
Other factors that affected the distribution ot pts among categones by 
multinomtel logistic regression analysis were baseline HDL-C, ape A-I, ape 
C-Ill:B, and Lp(n). FL reduced the number of i)1~ with prog by 27%, similar to 
the event reduction in LCAS 
Conclusion: Because most lesions are stable, mean \MLD =nay be a less 
usotul endpoint than lesion pregrossion/rogrE ssion. 
~ T h e  LIPID l¥1ah Impact of Lipid Lowering Therapy 
With Pravastatln on the Risk o~ Stroke 
H,D, White, R,J, Simos, J Watson, N, Anderson, G, Hankey, S, Simos, 
A, Tonkin, On beh,,~lf at the LIPID stud), group: Green Lane Hospital, 
Auckl~ncl, Not',, Zc~'dancl: Unri,orsity of Sydney: National Heart Foundahon, 
Australi,~ 
Epidemtological and recent clinical trial data support tl~o potential value of 
cholesterol lowering in reducing the risk of ischemic stroke, Tl~e LIPID trial 
was designed to assess tl~o long term effects of pravaslatin versus placebo 
on coronary heart disease (CHD) mortality in 9.014 patients with CHD and 
average cholesterol levels, Secondary aims included the effect of treatment 
on total stroke and on non-hemorrhagic stroke. Trial palients had a baseline 
total cholesterol of 4.0-7,0 mmol;L (155-271 mg/dl) and a history of acute 
myocardial infarction or hospitalization tar unstable angina. After an interim 
analysis showing a total mortality reduction with pravastatin (p • 0.003), the 
tdal is closing early with final analysis to occur after September 30, 1997 
When patient v~sits have been completed. 
As of August 31, 1997 there have been 384 shakes reported in 344 pa- 
tients. All reported strokes are classified blinded to treatment by an indepen- 
dent stroke assessment committee (including neurologists) as hemorrhagic, 
ischemic (large artery, lacunar, cardio-embolic, unknown), or of unknown 
type Each stroke requires a histnry of sudden onset of focal eeurological 
deficit lasting >24 hours. Ischemic stroke also requires no evidence of hem- 
orrhage on CT/MRI brain imaging or autopsy. In the first 94 cases reviewed of 
confirmed stroke, 64 were ischemic, 10 hemorrhagic and 20 unknown type. 
The LIPID trial will provide substantially more information on the potential 
benefit of cholesterol lowering treatment on stroke reduction suggested from 
eariie'~ trials. 
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11-~-2--~ Effect of Exercise on Left Vantrlcular Systolic 
~-  l~,lst: An E©hoeardlographl¢ Study in Normal 
Subjects 
J,M, Rothfeld, MD, Tischler, Univer.~r~/ ot~rmonf CoIl~o et A~,ctc!rm, 
E!orlingfon, Wrmont, U,~`1 
Elnckgrelmd: Left ventricutar (LV) twist or ceunterc;tockwlso rotation el the 
LV during systole is considered an important mechanism of beth normal 
election dynamics end generation et restonng tomes responsible for diastole 
suction, Alterations m twist I~avo been mpodod at rest in conjunction with 
depressed ventnctlla' function, However, the effects ql exorcise on twist m 
normal humans h~s t,el boon assessed 
Mpthods: Ton nem~al subjects undomtont symptom Iirettod treadmill Stress 
tests to oxhatistion. Two.dimee,'~ional echocardiography was podonned poor 
to and immediately alter exor~lse End.sySlolic twist was d, ete~nined by 
monstlnng relation o| the m~torelatora! paptllaq¢ mqscle about the center el 
the vonllicle in a hanstheracic short,a~is view. Data art) presented as mo,~n 
SD 
Results. Subiocts exofciso~ tar 13,4 t 5.5 mlntdes End sy'stoltc volume 
decreased significantly (2572 t 6,64 ml/m:" vs. '16.80 t 6.34 re~m:': p = 
0.0006) wlttl a colrespending increase In stroke volume (47.86 ~ 935 ml~" 
vs, 53,47 I 11 02 mVm~; p = 0,039) and ejection trachon (0.65 i 005 vs 
076 t 0,06; p . 0.0001). LV twist increased in all sublects (6.6 , 4.5 '~ vs 
14.7 t 66°; p .  0,000ti. 
Concluston.~: LV twist can be measured in patients undergoing stress 
ochocafdlography The magnitude of LV twist increases in normal sublects m 
response to exorcise. Thus, twist may be a mechanism el both augmontahon 
of conlractdo mechanics and maintenance at diastolic tilling dunng stress 
.o. ,n,,a., , , .  Ou,,. . .0a,,o. at ,.,re,re.t.le.lar 
Pressure Gradients and Flow Propagation From 
Color Doppler M-Mode Relates to Invasive 
Pressures In an Ischemic Canine Model 
M ,~h,g~ard, N.L. C, reenborg, H. K'mdo. L. Redn~ Jez. Cardiovascular 
Imagm 9. Department of Cardiology The Cleveland Clinic Founda#on. 
Cleveland. Ohlo, USA 
The puq3oso ot the study was to investigate the relationship bobs'sen nonm- 
vasive color M-mode tlow propagation and pressur9 gra~zcnts, c, nd mw.~we 
measured pressure changes in the left ventricle (LV) in an *schemic 0o 9 
model 
Methods; 5 open-chest anesthetized dogs were instrumented by a multi- 
sensor high hdolity catheter; one sensor in left atrium (LA). one at base and 
one at apex. Simultaneous pressure and Doppler recordings were obtained 
during baseline and ischomta induced by LAD occlusion. The color coded 
Doppler velocity map provides spatiotemporal velocity distribution along a 
streamline from LA into LV, and dmivatwos can be directly obtained to calcu- 
late pressero gradients the Euter equation. Automated elgenvector analys~s 
was used to compute the principal components of the E-wave, as an ellipse. 
with velocity weighted mean in space and time, spatial length and temporal 
width at the E-wave, and the angle el rotation '~-). 
Results: The intravontncular pressure gradient obtained from ealhcler 
(IVc) correlated well with the one estimated from Dopp!gr (IVd) (r = 0.71, p.  
0.01). IVc decreased from 1.06 ~ 010 to 0.67 ~ 022 mmHg Ins), and IVd 
from 0.B4 t- 0.11 to 0.61 ~. 0.18 mmHg Ins') dunng isehemia. Tau increased 
from 73 ~ 5 to 125 ! 20 ms (p.  0 05).., which is similar to flow propagation 
veloc{ty, increased tram 0.7 ~ 0.4 to 35 ~ 0.6 ° tP - 0.05). |Vc and IVd 
correlated with spatial components of the E wave, while tau correlated with 
temporal components. Thus, distribution of velocities in time reflects changes 
in relaxation, while distribution in space reflects pressure changes. 
Conclusion: Noninvasive quantification of IV pressure gradients and flow 
propagation from color Doppler M-mode is feasible; parameters correlate 
with invasive pressure measurements. 
